Mildly oxidized LDL induces activation of platelet-derived growth factor β-receptor pathway

• Published in: Circulation (New York, N.Y.) N.Y.), 2001-10, Vol.104 (15), p.1814-1821
• Main Authors: ESCARGUEIL-BLANC, Isabelle, SALVAYRE, Robert, VACARESSE, Nathalie, JÜRGENS, Günther, DARBLADE, Benoit, ARNAL, Jean-Francois, PARTHASARATHY, Sampath, NEGRE-SALVAYRE, Anne
• Format: Article
• Language: English
• Subjects: Aldehydes - metabolism; Aldehydes - pharmacology; Animals; Anti-Bacterial Agents - pharmacology; Antioxidants - pharmacology; Aorta - metabolism; Aorta - pathology; Arteriosclerosis - chemically induced; Arteriosclerosis - metabolism; Arteriosclerosis - pathology; Autocrine Communication; Biological and medical sciences; Blood vessels and receptors; Cells, Cultured; Ceramides - metabolism; Chloroquine - pharmacology; Diet, Atherogenic; Enzyme Inhibitors - pharmacology; Fundamental and applied biological sciences. Psychology; Humans; Hydrogen Peroxide - metabolism; Lipoproteins, LDL - metabolism; Lipoproteins, LDL - pharmacology; Macrolides; Male; Muscle, Smooth, Vascular - cytology; Muscle, Smooth, Vascular - drug effects; Muscle, Smooth, Vascular - metabolism; Oxidative Stress - physiology; Phosphorylation - drug effects; Rabbits; Reactive Oxygen Species - metabolism; Receptor, Platelet-Derived Growth Factor beta - metabolism; Signal Transduction - drug effects; Signal Transduction - physiology; Sphingomyelins - metabolism; Tyrosine - metabolism; Vertebrates: cardiovascular system
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/hc4001.097179

Mildly oxidized LDL (moxLDL) is thought to play a role in atherogenesis. MoxLDL induces derivatization of cell proteins and triggers a variety of intracellular signaling. We aimed to investigate whether moxLDL-induced protein derivatization may influence the activity of platelet-derived growth factor receptor beta (PDGFRbeta), a tyrosine kinase receptor of major importance in vascular biology and atherogenesis. In cultured rabbit arterial smooth muscle cells, moxLDL induces activation of the PDGFRbeta signaling pathway, as shown by PDGFRbeta tyrosine phosphorylation on Western blot and coimmunoprecipitation of SH2-containing proteins. The cellular events involved in the moxLDL-induced PDGFRbeta activation can be summarized as follows. Oxidized lipids from moxLDL trigger two phases of PDGFRbeta activation involving two separate mechanisms, as shown by experiments on cultured cells (in situ) and on immunopurified PDGFRbeta (in vitro): (1) the first phase may be mediated by 4-hydroxynonenal, which induces PDGFRbeta adduct formation and subsequent PDGFRbeta activation (antioxidant-insensitive step); (2) the second phase involves ceramide-mediated generation of H(2)O(2) (these steps being inhibited by tosylphenylalanylchloromethylketone, an inhibitor of ceramide formation, and by antioxidant BHT, exogenous catalase, or overexpressed human catalase). Because 4-hydroxynonenal-PDGFRbeta adducts are also detected in atherosclerotic aortas, it is suggested that this novel mechanism of moxLDL-induced PDGFRbeta activation may occur during atherogenesis. MoxLDL acts as a local autoparacrine mediator in the vascular wall, and PDGFRbeta acts as a sensor for both oxidized lipids and oxidative stress. This constitutes a novel mechanism of PDGFRbeta activation in atherosclerotic areas.